

Rostrum

Adverse Reactions to Illicit Drugs (Marijuana, Opioids, Cocaine) and Alcohol

Ine I. Decuyper, MD, PhD^{a,*}, Alicia Armentia, MD, PhD^{b,*}, Blanca Martín-Armentia, PhD^b,
Alfredo Corell Almuzara, MD, PhD^c, Didier G. Ebo, MD, PhD^d, and Hannelore A. Brucker, MD^e Antwerp, Belgium;
Valladolid, Spain; and Minneapolis, Minn

Drug allergy has been a research topic within the allergy field for decades. However, many drug reactions presumed to be of allergic nature are not and originate from different mechanisms. Drug-induced reactions can affect numerous organ systems, present with various symptoms, and have more than 1 mechanism of action. In this rostrum article, we want to give an overview of the different allergic and nonallergic reactions that can be expected with the (illicit) use of cannabis, cocaine, opioids, and alcohol. In addition, this article focuses on the different methods available to diagnose allergy related to these 4 drug types and highlight the pitfalls of nonallergic reactions or allergy “mimickers” complicating the diagnosis of true drug allergy. Finally, the impact on current medical practices and future research in support of the allergist in diagnosis and treatment of these medical problems is addressed. © 2021 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2021;■:■-■)

Key words: Marijuana; Cocaine; Heroin; Opium; Anaphylaxis; Drug allergy; Drug abuse; Anesthesia; Alcohol; Opioids; Papaver somniferum; Cannabis sativa

INTRODUCTION

The prevalence of drug allergy has been reported to be as high as 15% in hospitalized populations, but to date, the prevalence of hypersensitivity to drugs of abuse is unknown.¹ Some drug reactions are presumed to be of an allergic nature, but closer examination may reveal that they are not. Real drug-induced reactions can affect

numerous organ systems, present with various symptoms, and have more than 1 mechanism of action.² The diagnosis of drug allergy relies on the clinical history, physical examination, skin testing, *in vitro/ex vivo* tests, and drug provocation tests.³⁻⁶ The problem is that in the case of adverse reactions to illicit drugs, there are no commercialized diagnostic extracts, and challenges may be dangerous and can constitute legal and ethical issues.^{3,6} This article includes a background on the topic of illicit drug allergy including cannabis, cocaine, and opiates/opioids and adverse reactions to alcohol. It focuses on the impact on current medical practices and future research in support of the allergist in diagnosis and treatment of these medical problems.

CANNABIS ALLERGY

Cannabis is an illicit drug derived from the flower tops of the cannabis plant, mostly the *sativa* or *indica* varieties. Its preparations are otherwise known as “weed,” “hash,” or marijuana and are the most widespread (ab)used drugs throughout the world (Figure 1).⁷

The active ingredients are called cannabinoids, of which delta-9-tetrahydrocannabinol and cannabidiol are the most well known. Tetrahydrocannabinol is (ab)used mainly in a recreational setting for its psychoactive effects. However, there is an increasing trend in decriminalizing and even legalizing tetrahydrocannabinol-rich cannabis use around the world, allowing for use in a medical setting as an antispasmodic, analgesic, anxiolytic, and antiemetic drug.⁸ However, cannabidiol has grown in popularity for various benefits, some more evidence-based than others. One of the best documented benefits is found to be its antiepileptic activity in otherwise therapy-resistant Dravet and Lennox-Gastaut syndromes.⁹ Although research has proven that cannabis and its components can be of significant use in medical applications, certain dangers and adverse effects cannot be excluded when its use is uncontrolled, such as is seen when the drug is used recreationally.¹⁰ Cannabis allergy is one of these adverse effects. Although research on the topic is still in its infancy, and the prevalence of such an allergy remains unknown, different research groups around the world have shown that a cannabis allergy can manifest severe and generalized symptoms with detrimental effects on a patient's health and quality of life.¹¹⁻¹⁴ As such, in this article, we aim to describe cannabis allergy and discuss the difficulty discriminating “allergic” symptoms from physiological effects, as well as the challenges associated with diagnosis, and finally debate possible future diagnosis and treatment options.

Physiological effects or allergic symptoms of cannabis?

Although we now know that cannabis allergy exists and can express various symptoms (Figure 2), it can remain challenging

^aDepartment of Pediatrics, University Hospital of Antwerp, Antwerp University, Antwerp, Belgium

^bAllergy Service, Hospital Universitario Río Hortega, Valladolid University, Valladolid, Spain

^cImmunology Department, Valladolid University, Valladolid, Spain

^dInfla-Med, University of Antwerp, Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp/University of Antwerp, Antwerp, Belgium

^eSouthdale Allergy and Asthma Clinic, LLC, Minneapolis, Minn

*These authors contributed equally to this work.

Conflict of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication March 1, 2021; revised April 19, 2021; accepted for publication April 25, 2021.

Available online ■■

Corresponding author: Hannelore A. Brucker, MD, 5153 Abercrombie Dr, Minneapolis, MN 55439. E-mail: habrucker@hotmail.com.
2213-2198

© 2021 American Academy of Allergy, Asthma & Immunology
<https://doi.org/10.1016/j.jaip.2021.04.061>

Abbreviations used

BAT- Basophil activation test
 Can s- Cannabis sativa
 LA- Local anesthetic
 nsLTP- Nonspecific lipid transfer protein
 SPT- Skin prick test
 sIgE- Specific IgE

to differentiate symptoms mediated by a hypersensitivity reaction from “normal” cannabis effects for several reasons.

First of all, it has been shown that both cannabis smoking and gastrointestinal consumption can induce a conjunctival injection quite similar to what is seen in allergic rhinoconjunctivitis, even if the subject is not sensitized to cannabis.¹⁶ Multiple pulmonary investigations have discussed cannabis’ effects on the bronchi, showing that short-term effects could induce bronchodilation,¹⁷ whereas chronic use is more often linked to bronchoconstriction, which can be hard to clinically differentiate from asthma/allergy.^{18,19} Multiple reports stemming from occupational cannabis exposure have suggested that cutaneous cannabis contact and/or contact with the chemical pesticides used in plantations can induce an irritating reaction^{20,21} that can be confused with allergic contact urticaria and/or eczema as seen in cannabis allergic reactions.^{11,20-25}

Diagnostic challenges for cannabis allergy

As with most allergies, a diagnosis of cannabis allergy should first be based on a detailed history and would ideally include a challenge test. The latter is currently a big hurdle for multiple reasons. For one, in most countries, cannabis is still banned, thus making challenge tests illegal. Second, the physiological effects of cannabis can cloud the interpretation of the challenge because inhaled cannabis can cause (rhino)conjunctivitis and affect the bronchi (constriction/dilatation depending on cited research).^{19,26,27} Finally, the drug induces a mind-altering state, complicating the patient’s symptom assessment and recollection of experienced symptoms. The lion’s share of reports on cannabis allergy make note of an IgE-mediated allergy that has been linked to different allergenic components (Table 1) such as *Cannabis sativa* (Can s) 3 and Can s 4 (oxygen-evolving enhancer protein 2) and more recently also Can s 2 (Cs-profilin) and Can s 5 (Cs-*Betula verrucosa* 1 homologue).^{14,28-30} Because some of these allergens belong to a superfamily of panallergens including the nsLTP (nonspecific lipid transfer protein) family, profilins, and *B verrucosa* 1 homologues, cannabis-allergic patients can experience cross-allergies with multiple plant-foods and *Hevea latex*.^{11,12,29,31} This type of cannabis allergy can be diagnosed with different allergy diagnostics, such as skin prick tests (SPTs), specific IgE (sIgE) quantification, and basophil activation tests (BATs), using crude extracts or purified/recombinant proteins.¹⁵ As can be expected, test specificity seems to be best using recombinant allergens,^{11,13,32} whereas sensitivity is found to be superior when using crude cannabis extracts. However, when using the latter, it is important to keep in mind that a significant number of pollen-sensitized individuals can exhibit clinically irrelevant results.¹¹ Anyhow, because the scientific exploration of cannabis allergy has only just begun, there are no standardized and validated tests on the market as of yet. There is an sIgE hemp (ImmunoCAP) available from Phadia, Thermo Fisher (Uppsala, Sweden), but for research purposes only. So, when there is a

clinical suspicion of a cannabis allergy case, as illustrated by the diagnostic algorithm in Figure 2, we would pragmatically suggest performing SPT/sIgE with a crude extract (preferably from the patient’s own cannabis materials) because false negatives are expected to be few, and further confirmation with component-resolved diagnostics can follow, if available.¹⁵

When it comes to IgE-independent cannabis allergies, to our knowledge, only 1 report has looked into a type 4 hypersensitivity reaction causing contact dermatitis.³³ Finally, in the occupational cannabis setting, there is a well-documented body of evidence indicating that cannabis-induced byssinosis can occur, a form of occupational asthma attributed to organic dust exposure, derived in part from naturally occurring microorganisms.³⁴ Diagnosis of byssinosis starts with a detailed history because symptoms are often solely respiratory, are worst on the first day of exposure, diminish the following days, and reemerge after a period of nonexposure. In addition, spirometry is a helpful tool to objectify cannabis-related bronchoconstriction. A computed tomography scan (millimetric) can further aid in the diagnosis of byssinosis and other types of pneumonitis as can fluids obtained during bronchoscopy (bronchial alveolar lavage) and lung diffusion tests such as transfer factor of the lung for carbon monoxide.

Prospects for the future

The current evidence has established that IgE-mediated cannabis allergy is a true allergy entity that can manifest severe and generalized symptoms with various cross-reactivities. Nevertheless, prediction of its prevalence remains difficult, in part because of the illegal status of the drug, and thus the impact of cannabis allergy on society should still be further explored. In addition, several allergens have been detected, with most recently the confirmation of Can s 2 (profilin), Can s 4 (oxygen-evolving enhancer protein 2), and Can s 5 (a *B verrucosa* 1 homologue) as potential cannabis allergens.^{28,30} Still, the IgE-reactivity profile seems to be incomplete and remains food for thought. Finally, for the time being, there is no available cure for IgE-mediated cannabis allergy nor for the cannabis-related plant-food allergies. Therefore, strict avoidance measures remain of the utmost importance. These measures comprise a complete stop of further cannabis exposure and avoidance of exposures to allergens implicated in the individual cross-reactivity syndrome. Although some case reports claim successful desensitization,^{35,36} further research is needed to investigate its true potential as cannabis allergy treatment.

COCAINE ALLERGY

Natural cocaine is an alkaloid extracted from the leaves of the coca shrub *Erythroxylum coca* and *E novogranatense*. The harvested leaves are macerated with various solvents. This process results in a pasty substance (“coca paste”) that contains 80% cocaine and is purified to “coca base.” Through reaction with hydrochloric acid, cocaine powder is formed while the solvents and acids are removed. Cocaine powder can be used via oral, sublingual, intravenous, intramuscular, and subcutaneous routes. The nasal use is called snorting. If cocaine hydrochloride is precipitated, it can be smoked as “free-base cocaine” or “crack (rock).”³⁷ Bronchospasm can occur in patients smoking cocaine,³⁸⁻⁴⁰ often in patients with a history of asthma. Research has shown that cocaine use may be responsible for asthma onset, acute asthma exacerbations (which may require intubation and invasive ventilation), and asthma-related death.⁴¹




FIGURE 1. Cannabis, coca leaf, and poppy seed in their original form and how it is used. *Opiates are derived from natural sources, whereas opioids are derived from synthetic sources.

Smoking crack cocaine and nasal insufflation of cocaine increases the risk of emergency department visits due to severe angioedema.⁴¹ Studies that investigate the prevalence of potentially harmful adulterants in crack have found that the most prevalent adulterant is lidocaine (92%), followed by phenacetin (69%) and levamisole (31%).⁴² The immunomodulatory adjuvant and antihelminth levamisole is increasingly used as an adulterant in cocaine worldwide. Neutropenia, agranulocytosis, leukoencephalopathy, and vasculitis in cases associated with levamisole-adulterated cocaine have been described.⁴³

In a series of 211 patients with symptoms related to cocaine abuse,³⁷ 41 were diagnosed as cocaine allergic by positive challenge, prick, and sIgE tests to coca leaves.

Some local anesthetics (LAs) derived from cocaine (benzocaine, dibucaine, procaine) and cases of anaphylaxis after LAs have been described,^{44,45} but overall IgE-mediated (immediate) allergy to LAs is rare.⁴⁴ The major source of delayed reactions to LAs is direct contact resulting in allergic contact dermatitis, especially by dibucaine-containing perianal medicaments,⁴⁶ although benzocaine has been identified as a leading sensitizer.^{38,40,41,45}

Until now, as for cannabis allergy, there are no efficient commercial diagnostic techniques that demonstrate an IgE-mediated allergy to cocaine. Studies showing that cocaine-dependent patients respond positively to prick and sIgE tests to coca leaf extracts led to investigate the use of these

tests in patients with hypersensitivity to cocaine-derived LAs.³⁷ Component-resolved diagnosis has also been used to determine its sensitivity and sensibility in detecting sensitivity to the different molecules of complex allergens, such as cocaine, which is often adulterated, or coca leaf extracts. Using a large database,³⁷ the study focused on patients with anaphylaxis to local anesthesia and patients with drug abuse and symptoms of asthma and anaphylaxis after cocaine use. The diagnostic yield (sensitivity, specificity, and predictive value) of allergy tests using cocaine and coca leaf (Figure 1) extracts in determining cocaine allergy was assessed, taking a positive challenge as the criterion standard. This research found that SPTs and sIgE to coca leaves (coca tea) had a good sensitivity and specificity for the diagnosis of cocaine allergy and LA-derived allergy.

In summary, cocaine allergy may provoke life-threatening symptoms and should be considered in cocaine-dependent patients with poorly controlled asthma and in candidates for surgery. Cocaine hypersensitivity may be tested with a simple and practical method such as SPTs and sIgE determination to cocaine extracts in the clinical situation. However, more research is necessary to define the exact nature of the allergic compounds and develop standardized and commercially available tests.⁴⁷ A correlation of such tests with serum tryptase, plasma histamine, and, if available, BAT would add to the validation of allergic reactions.^{47,48}




FIGURE 2. Proposed stepwise diagnostic approach for cannabis allergy. Adapted from Decuyper II, Rihs HP, Van Gasse AL, Elst J, De Puyssseleir L, Faber MA, et al. Cannabis allergy: what the clinician needs to know in 2019. *Expert Rev Clin Immunol* 2019;15:599-606,¹⁵ with permission from Taylor & Francis Ltd.

TABLE I. Allergens from Can s indexed in the allergen list of the IUI

IUIS nomenclature	Allergen class		Molecular weight (kDa)	Available from	Reference
	Genbank Nucl	Genbank Prot			
Can s 2	Profilin XM030636604.1 XP030492464.1		14	H.P. Rihs	28
Can s 3	nsLTP HE972341 CCK33472		9	H.P. Rihs	11,29
Can s 4	Oxygen-evolving enhancer protein 2 XM030626708.1 XP030482568.1		27.3	H.P. Rihs	30
Can s 5	<i>Betula verrucosa</i> 1 homologue JN6792251.1 AFN42528.1		17.7	H.P. Rihs	28

IUIS, International Union of Immunological Societies.

Column 1 gives an overview of known cannabis allergens, listed with the name assigned by the International Union of Immunological Societies. Column 2 lists the corresponding sequence data of the GenBank for the Nucleotide (Nucl) and the Protein (Prot). The GenBank is a part of the International Nucleotide Sequence Database Collaboration.

ALLERGY TO OPIATES AND OPIOIDS

Opium is the dried sap that is drained from the seed pod of the opium plant *Papaver somniferum*. Morphine and opioid-based drugs are created in refineries. A series of chemical reactions changes morphine to heroin powder (Figure 1). Opioids and opiates constitute an important part of (illicit) drug abuse, but on the other hand, they are also potent analgesics of vital importance in a hospitalized setting. An important characteristic

of opiates, such as morphine and codeine, is the fact that they can trigger a histamine release from skin mast cells mimicking allergic reactions. Methadone, tramadol, and fentanyl and its derivatives do not have this property.⁴⁹ This nonspecific histamine release makes the traditional allergy SPT result to opiates and (semi-)synthetic opioids difficult to interpret. It is challenging to differentiate IgE-mediated opiate allergy from nonspecific reactions.

For several decades, case reports, retrospective studies, and laboratory investigations have demonstrated that heroin inhalation can be associated with increased asthma symptoms (possibly because of nonspecific histamine release) and reduced pulmonary function. Smoking or nasal insufflation of heroin increases the risk of emergency department visits and hospitalizations for asthma.³⁸

In light of the diagnostic challenges for opiates, researchers debate whether diagnostics based on opium seed extracts are helpful. Spanish researchers have explored heroin sensitization in a cannabis-allergic, multidrug-addicted population, to try and prevent hypersensitivity reactions to opioids, during surgery.^{13,32,50} To avoid the nonspecific histamine release of opiates in SPTs, opium seed extracts (Figure 1) were used as a substitute for heroin.⁵¹ Two hundred three patients from the said population were selected with hypersensitivity reactions during surgery, and confirmed heroin abuse. Patients sensitized to heroin (defined as a positive challenge) or with severe clinical reactions during surgery, responded to *P somniferum* seed tests (positive IgE and skin test results). Opium seed SPTs and sIgE, especially the oil body fraction, were more sensitive (64.2%) and specific (98.4%) than morphine, codeine, and rocuronium tests for opioid sensitivity. However, a Belgian group also explored sIgE to morphine and opium seed extracts additionally to BAT with morphine/codeine in 22 individuals; it found that positive sIgE results to poppy seed and morphine were not per se predictive for genuine opiate allergy. However, BAT seemed promising to help discriminate clinical reactivity and sensitization.⁵² Genuine IgE-mediated anaphylaxis to opiates and synthetic opioids (methadone, tramadol, and fentanyl and its derivatives) is rare.⁴⁹ Little or no evidence exists between cross-reactivity of the different opioid subclasses, but cross-reactivity between morphine and codeine was reported.^{53,54} IgE and skin tests for the oil body fraction of *P somniferum* had the highest sensitivity for sensitization to opioids. Another concept regards nonspecific mediator release, likely because of occupation of the Mas-related G protein-coupled receptor X2, which is mainly expressed by skin mast cells, as much more prevalent.^{49,54} At present there is no reliable diagnostic to document such Mas-related G protein-coupled receptor X2 reactions that are clinically and biologically indistinguishable from IgE-mediated reactions.⁵⁵ A possible diagnostic approach could include *ex vivo* basophil activation experiments, because these cells barely express this receptor, and do not react nonspecifically to Mas-related G protein-coupled receptor X2 agonists.^{52,56}

A major problem with illicit drugs such as heroin is that their illegal status results in varying drug compositions, ingredients, and possible contaminants. The unknown drug composition can be the cause of “hidden” allergens and may result in serious and sometimes even life-threatening symptoms as exemplified by a case of a heroin addict displaying an endophthalmitis believed to have resulted from fungal contaminants from his heroin as well as an anaphylactic reaction to lemon particles contaminating the drug used.⁵⁷

ADVERSE REACTIONS TO ALCOHOLIC BEVERAGES

There are many causes for adverse reactions to alcohol. These reactions can be nonimmunologic (pharmacologic) and immunogenic due to various ingredients of alcoholic beverages.

Alcohol consumption, in addition, has an influence on the presentation of certain diseases and reactions to medications. The processing of alcoholic beverages and additives may contribute to the reactions to alcohol.

Hereditary enzyme deficiency of the alcohol metabolism

One of the most common adverse reactions to alcohol is the so-called Asian Flush syndrome characterized by facial flushing, headache, nausea, dizziness, and cardiac palpitations after consumption of alcoholic beverages. There are 2 enzymatic steps to metabolize ethanol: The first is the production of acetaldehyde by the enzyme alcohol dehydrogenase (ADH), and the second is the breakdown of acetaldehyde by aldehyde dehydrogenase (ALDH) (Figure 3). These enzymes are encoded by different genes, which occur in several variants (alleles). The enzymes encoded by these alleles can differ in the rate at which they metabolize alcohol.⁵⁹ In the Asian Flush syndrome, there is a mutation of ALDH2*1 to ALDH2*2 as the most common cause.⁶⁰⁻⁶² This mutation occurs in 560 million people (8%) of the world population. Its highest prevalence (35%-45%) is in people of East-Asian descent, hence its name. The situation is even made worse if another mutation in the first ethanol-metabolizing enzyme accompanies the problem: a mutated ADH, specifically ADH1B*2.⁶⁰ This mutation also occurs more commonly in people of Asian descent. ADH1B*2 metabolizes ethanol fairly fast to acetaldehyde and if ALDH2 does not work, the result is an increase in the acetaldehyde level. Acetaldehyde has been implicated in a marked increase in cancer of the upper digestive tract, especially esophageal cancer.⁶² Although experiments have been performed to introduce the ALDH2 coding sequence into mice with the help of an adeno-associated virus gene transfer to correct the deficiency state, the applications for humans may still take many years.⁶³

Immunogenic reactions to alcoholic beverages

In the allergy literature are reports of anaphylactic reactions to ethanol itself.^{64,65} The studies mentioned are few, and usually involve the case history of sometimes poorly documented single patients. Skin tests with diluted acetic acid were used, the results of which were positive in most patients and negative in controls. However, almost all patients tolerated vinegar. In addition, provocation test results with ethanol, most of them blinded, were positive in all patients. It is rather difficult to explain the pathogenetic mechanism of these rather rare reactions. Newer research concentrates more on the multitude of components in alcoholic beverages.

One important allergen that occurs in alcoholic beverages is a lipid transfer protein (nsLTP) resistant to heat and acid.²⁹ Patients sensitized to nsLTP may be asymptomatic, but their reactions seem to be more severe when they are sensitized to the food nsLTP alone.¹⁵ An nsLTP is present in grape *Vitis vinifera* (Vit v 1) and therefore in wine. nsLTPs are also present in beer deriving from different cereals, which are germinated and heated to obtain malt. They occur in barley, *Hordeum sativa* and *vulgare* (Hor v 7k-nsLTP), wheat, *Triticum aestivum*, and maize, *Zea mays* a. o.⁶⁶ Another nsLTP occurs in hops, *Humulus lupulus*, added for bitterness and flavor. These nsLTPs in sensitized patients, who consume wine or beer, can lead to IgE-mediated reactions of different severity that may include anaphylaxis. Such allergic reactions can be amplified by concomitant exercise




FIGURE 3. The breakdown of ethanol to acetaldehyde by ADH and the breakdown of acetaldehyde by ALDH to acetate. Reprinted with permission from Chhabra.⁵⁸

or use of nonsteroidal anti-inflammatory drugs.¹⁵ Wheat-containing beer, especially when consumed with additional wheat products, can lead to wheat-dependent exercise-induced anaphylaxis due to an antibody to wheat- γ -gliadin.^{67,68} In wheat beer (Weissbier), barley is mixed with 50% of wheat malt. Newer proteomic and peptidomic analysis shows that it contains gluten epitopes and is therefore incompatible with a gluten-free diet for patients with celiac disease.⁶⁹ In addition, Weissbier, because of the brewing technique, contains more yeast-derived products, mainly from *Saccharomyces spp*, than other beers. An IgE-mediated yeast allergy is exceptionally rare. One of very few case reports establishes an IgE-mediated sensitivity to yeast in beer, wine, and cider.⁷⁰ Yeast is added in the beer-making process and occurs naturally in wine but may also be added to red wine must or to the juice from white wine. ImmunoCAP tests are available for *Saccharomyces* and for barley/malt. An interesting IgE-mediated allergy to red and white wine through oral sensitization to Hymenoptera venom was reported.⁷¹ Hymenoptera venom can contaminate fresh pressed wine because stinging insects are attracted to sugars and alcohol in ripe grape bunches. The allergic reaction occurred only to fresh pressed wine, and not to wine aged up to 1 year. In old wines, the fermentation decomposes the venom. A rare report of anaphylaxis to gold tequila but not to white tequila was reported in a patient allergic to oak pollen.⁷² Gold tequila is aged for months or years in oak barrels, whereas clear tequila undergoes little to no aging.

Discussion of the clinical implication of the presence of histamine in alcohol

The primary fermentation step produces alcohol and during the secondary fermentation biogenic amines, such as histamine, are formed.⁷³ The histamine content in beer, white, and red wine is 176, 83, and 260 mg/kg, respectively.⁷⁴ Scientific research of adverse reactions to ingested histamine, accused of causing symptoms of headache, flushing, diarrhea, a.o. due to deficient ability to metabolize histamine,⁷⁵ did not reveal an isolated clinical picture.⁷⁶ Laboratory tests to study reactions to

exogenous histamine are not reliable. Double-blind, placebo-controlled trials with histamine provocation triggered symptoms in healthy subjects.⁷⁷ A low histamine diet is of minimal benefit.⁷⁸ More scientific evidence is still required to define, diagnose, and treat symptoms of assumed adverse reactions to histamine.^{75,76}

Fining agents in wine

Fining is a process in winemaking to remove small insoluble and colloidal particles and astringent compounds such as tannins. Fining agents are ovalbumin and lysozyme (extracted from hen's egg), cow's milk, casein, fish gelatin, and isinglass (from swim bladders of sturgeon, cod, or hake). The fining process prevents later clouding of the wine, so that it remains stable for storage, transport, and temperature conditions.⁷³ Only wines with a high concentration of fining agents resulted in positive skin prick test results in patients with a food allergy to the fining agent.^{79,80} A preliminary study with immunoblotting to detect and quantify ovalbumin and casein in bottled wine showed the samples to be allergen free.⁸¹ Another study reports negligible residual food allergens in wine.⁸² Although there is concern regarding labeling of wines for food-allergic patients in many countries, these studies make a reaction to fining agents in IgE-mediated food-allergic patients either rare or highly unlikely. Many wine-producing countries will run more large-scale studies to ensure the safety of handling the removal process of fining agents.

Sulfites in wine

Small amounts of sulfites occur naturally in all wines. Sulfites are added during the winemaking process to arrest fermentation, to act as preservatives, and to prevent spoilage from oxidation and protect from bacteria. Sulfites are at a much higher concentration in white than in red wine.⁷³ Previous studies indicated that wine consumption was associated with worsening of asthma symptoms, but high- and low-sulfite wine challenges did not support a role for sulfites in patients with stable asthma.⁸³ However, patients with asthma, mostly with IgE-independent

steroid-dependent asthma, in as many as 5% of cases may react with mild wheezing or severe bronchoconstriction to sulfite-containing beverages.⁸⁴ The mechanism of sulfite-induced asthma is controversial. An IgE mechanism has been suspected but not proven. A cholinergic reflex, a partial deficiency of the sulfite-oxidase enzyme, responsible for the final oxidizing of sulfite to inactive sulfate, and a kinin mechanism have also been debated. Reaction to sulfites seems to be a nonspecific response, and specific IgE antibodies to sulfites have not been identified.⁸⁵

Specific alcohol-related effects on medical conditions

Patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis can experience respiratory reactions with alcohol ingestion.⁸⁶ In aspirin-exacerbated respiratory disease, the severity of aspirin-induced reactions during aspirin challenge correlated with the severity of the alcohol-induced reaction. Because patients with aspirin-exacerbated respiratory disease have a higher excretion of urinary leukotrienes, a leukotriene-dependent mechanism may underlie the alcohol-induced respiratory reactions.

Ethanol can cause systemic contact dermatitis. It is used as a topical penetration enhancer in transdermal medications because it removes lipids from the skin. Use of such “patches” over a prolonged period of time can lead to ethanol sensitization, resulting in a delayed (8 hours) cutaneous reaction.⁸⁷ Patients with chronic urticaria often notice an exacerbation after ingestion of alcohol.⁸⁸ Rosacea flushing, among other factors, is known to be triggered by alcohol, recently thought to be caused by neuronal signaling.⁸⁹ In patients with Hodgkin lymphoma, pain at the site of bone or lymph node involvement may appear minutes after ingestion. This alcohol-related pain is highly specific for the diagnosis and occurs in 1.5% to 5% of patients⁹⁰; the mechanism is unknown. One of the factors provoking flushing in carcinoid syndrome is alcohol.⁹¹ The exacerbation of symptoms of mastocytosis has been thought, among other factors, to be influenced by alcohol due to its content of histamine.⁹²

Alcohol-medication interactions

Many medication reactions involve an interference with the activity of ADH increasing the level of acetaldehyde, which causes facial flushing, nausea, vomiting, tachycardia, and hypotension. In this category are medications such as disulfiram, cephalosporins with a methylthiotetrazole side chain, and chlorpropamide.⁹²⁻⁹⁴ Another enzyme system that likely plays a role in alcohol-medication interactions is the P450 reductase and the CYP2E1.⁹⁵

However, not all disulfiram-like reactions are yet clarified. One such reaction is a disulfiram-like reaction to metronidazole and other nitroimidazoles in patients consuming alcohol. The interaction between metronidazole and alcohol does not occur in all patients, suggesting an individual susceptibility.⁹³ Other interesting reactions may occur to the topical calcineurin inhibitors, tacrolimus and pimecrolimus. Five to 10 minutes after a local application not only the treated area can become erythematous but flushing of healthy skin, for example, the face, may also occur.⁹³ An unusual reaction in a patient who tolerated topical tacrolimus for years occurred when dupilumab was started.⁹⁶ Future research will reveal more information on alcohol-related medication reactions.

CONCLUSIONS

In the field of allergy, much has already been discovered concerning allergies to pollen, food, and plant products. However, the investigations of (illicit) drug allergies seem to be lagging

behind. This review highlights what is known about allergies and other adverse reactions to cannabis, cocaine, opiates, opioids, and alcohol. In addition, several hurdles and points of attention specific to this field of research are discussed in the hope to facilitate future qualitative research and help progress our knowledge about (illicit) drug allergy.

Apart from a patient's reticence to discuss their drug use, it is important to keep in mind that many drugs induce a mind-altering state with different sensations of time and space as well as a varying degree of retrograde amnesia. Thus, the patient might experience symptoms differently, impacting, for example, the accuracy of the reported time between contact and onset of symptoms as well as perceived duration of symptoms, details that are of paramount importance in allergy history taking.

This review shows that cocaine use should be systematically considered in the case of asthma exacerbations. Cannabis, cocaine, or heroin use must be considered in cases of acute respiratory symptoms or asthma exacerbation in young people, and practitioners must help illicit substance users to stop their consumption.^{40,97}

It is necessary to find reliable diagnostic methods based on *in vivo* and *in vitro* tests using extracts of the natural plant source or recombinant proteins in a large series of habitual heroin, cocaine, and cannabis consumers and atopic and nonatopic controls. In patients sensitized to these drugs, antibodies can be measured for many years, which could have legal and forensic implications, and could allow changes in drugs such as opium and cocaine-derived anesthetics in patients about to undergo surgery. It is hoped that the outlined factors involved in adverse reactions to alcohol will support a stepwise analysis of situations seen in the clinic.

REFERENCES

1. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. *Br J Clin Pharmacol* 2011;71:684-700.
2. Demoly P, Castells M. Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium. *World Allergy Organ J* 2018;11:42.
3. Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized controlled trial. *J Allergy Clin Immunol Pract* 2019;7:2163-70.
4. Khan DA, Solensky R. Drug allergy. *J Allergy Clin Immunol* 2010;125:S126-37.
5. Chiriac AM, Demoly P. Drug allergy diagnosis. *Immunol Allergy Clin North Am* 2014;34:461-71, vii.
6. Ramsey A, Sheikh A. Innovations in health care delivery: drug allergy. *J Allergy Clin Immunol Pract* 2019;7:2143-50.
7. United Nations. World Drug Report 2020. United Nations; 2020. Available from: <https://wdr.unodc.org/wdr2020/index2020.html>. Accessed June 14, 2021.
8. Amin MR, Ali DW. Pharmacology of Medical Cannabis. In: Bukiya A, editor. *Recent Advances in Cannabinoid Physiology and Pathology. Advances in Experimental Medicine and Biology*, vol 1162. Cham, Switzerland: Springer; 2019.
9. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. *Epilepsy Behav* 2014;41:277-82.
10. World Health Organization. The health and social effects of nonmedical cannabis use. World Health Organization; 2016. Available from: <https://apps.who.int/iris/handle/10665/251056>. Accessed June 14, 2021.
11. Decuyper II, Van Gasse AL, Faber MA, Elst J, Mertens C, Rihs HP, et al. Exploring the diagnosis and profile of cannabis allergy. *J Allergy Clin Immunol Pract* 2019;7:983-9.e5.
12. Armentia A, Castrodeza J, Ruiz-Munoz P, Martinez-Quesada J, Postigo I, Herrero M, et al. Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users. *Allergol Immunopathol (Madr)* 2011;39:271-9.
13. Rihs HP, Armentia A, Sander I, Bruning T, Raulf M, Varga R. IgE-binding properties of a recombinant lipid transfer protein from *Cannabis sativa*. *Ann Allergy Asthma Immunol* 2014;113:233-4.
14. Nayak AP, Green BJ, Sussman G, Berlin N, Lata H, Chandra S, et al. Characterization of *Cannabis sativa* allergens. *Ann Allergy Asthma Immunol* 2013;111:32-7.

15. Decuyper II, Rihs HP, Van Gasse AL, Elst J, De Puyseleir L, Faber MA, et al. Cannabis allergy: what the clinician needs to know in 2019. *Expert Rev Clin Immunol* 2019;15:599-606.
16. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. *Prog Retin Eye Res* 2008;27:501-26.
17. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. *J Clin Pharmacol* 2002;42:71S-81.
18. Tashkin DP, Coulson AH, Clark VA, Simmons M, Bourque LB, Duann S, et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. *Am Rev Respir Dis* 1987;135:209-16.
19. Zeiger JS, Silvers WS, Winders TA, Hart MK, Zeiger RS. Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network. *Ann Allergy Asthma Immunol* 2021;126:401-410.e1.
20. Decuyper II, Van Gasse A, Faber MA, Mertens C, Elst J, Rihs HP, et al. Occupational cannabis exposure and allergy risks. *Occup Environ Med* 2019;76:78-82.
21. Vanhove W, Cuypers E, Bonneure AJ, Gotink J, Stassen M, Tytgat J, et al. The health risks of Belgian illicit indoor cannabis plantations. *J Forensic Sci* 2018;63:1783-9.
22. Ebo DG, Swerts S, Sabato V, Hagendorens MM, Bridts CH, Jorens PG, et al. New food allergies in a European non-Mediterranean region: is *Cannabis sativa* to blame? *Int Arch Allergy Immunol* 2013;161:220-8.
23. Majmudar V, Azam NA, Finch T. Contact urticaria to *Cannabis sativa*. *Contact Dermatitis* 2006;54:127.
24. Rojas Perez-Ezquerro P, Sanchez-Morillas L, Davila-Fernandez G, Ruiz-Hornillos FJ, Carrasco Garcia I, Herranz Manas M, et al. Contact urticaria to *Cannabis sativa* due to a lipid transfer protein (LTP). *Allergol Immunopathol (Madr)* 2015;43:231-3.
25. Williams C, Thompstone J, Wilkinson M. Work-related contact urticaria to *Cannabis sativa*. *Contact Dermatitis* 2008;58:62-3.
26. Angelina A, Perez-Diego M, Lopez-Abente J, Palomares O. The role of cannabinoids in allergic diseases: Collegium Internationale Allergologicum (CIA) Update 2020. *Int Arch Allergy Immunol* 2020;181:565-84.
27. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. *Arch Intern Med* 2007;167:221-8.
28. Ebo DG, Decuyper II, Rihs H-P, Mertens C, Van Gasse AL, van der Poorten M-LM, et al. IgE-binding and mast cell activating capacity of the homologue of the major birch pollen allergen and profilin from *Cannabis sativa*. *J Allergy Clin Immunol Pract* 2021;9:2509-12.e3.
29. Gamboa P, Sanchez-Monge R, Sanz ML, Palacin A, Salcedo G, Diaz-Perales A. Sensitization to *Cannabis sativa* caused by a novel allergenic lipid transfer protein, Can s 3. *J Allergy Clin Immunol* 2007;120:1459-60.
30. Decuyper II, Rihs HP, Mertens CH, Van Gasse AL, Elst J, De Puyseleir L, et al. A new cannabis allergen in Northwestern Europe: the oxygen-evolving enhancer protein 2 (OEEP2). *J Allergy Clin Immunol Pract* 2020;8:2421-2424.e2.
31. Faber MA, Sabato V, Bridts CH, Nayak A, Beezhold DH, Ebo DG. Clinical relevance of the *Hevea brasiliensis* lipid transfer protein Hev b 12. *J Allergy Clin Immunol* 2015;135:1645-8.
32. Armentia A, Herrero M, Martin-Armentia B, Rihs HP, Postigo I, Martinez-Quesada J. Molecular diagnosis in cannabis allergy. *J Allergy Clin Immunol Pract* 2014;2:351-2.
33. Watson ES, Murphy JC, Turner CE. Allergenic properties of naturally occurring cannabinoids. *J Pharm Sci* 1983;72:954-5.
34. Green BJ, Couch JR, Lemons AR, Burton NC, Victory KR, Nayak AP, et al. Microbial hazards during harvesting and processing at an outdoor United States cannabis farm. *J Occup Environ Hyg* 2018;15:430-40.
35. Engler DB, Malik AA, Saraf SK, Dargel LA. Severe marijuana allergy controlled with omalizumab. *J Allergy Clin Immunol* 2013;131:AB215.
36. Kumar R, Gupta N. A case of bronchial asthma and allergic rhinitis exacerbated during cannabis pollination and subsequently controlled by subcutaneous immunotherapy. *Ind J Allergy Asthma Immunol* 2013;27:143-6.
37. Armentia A, Martin-Armentia B, Martin-Armentia S, Ruiz-Munoz P, Quesada JM, Postigo I, et al. Cocaine allergy in drug-dependent patients and allergic people. *J Allergy Clin Immunol Pract* 2018;6:201-7.
38. Self TH, Shah SP, March KL, Sands CW. Asthma associated with the use of cocaine, heroin, and marijuana: a review of the evidence. *J Asthma* 2017;54:714-22.
39. Ettinger NA, Albin RJ. A review of the respiratory effects of smoking cocaine. *Am J Med* 1989;87:664-8.
40. Underner M, Perriot J, Peiffer G, Jaafari N. Asthma and cocaine use [in French]. *Rev Mal Respir* 2019;36:610-24.
41. Castro-Villamor MA, de las Heras P, Armentia A, Duenas-Laita A. Cocaine-induced severe angioedema and urticaria. *Ann Emerg Med* 1999;34:296-7.
42. Ribeiro M, Trevizol AP, Frajzinger R, Ribeiro A, Speierl H, Pires L, et al. Adulterants in crack cocaine in Brazil. *Trends Psychiatry Psychother* 2019;41:186-90.
43. Brunt TM, van den Berg J, Pennings E, Venhuis B. Adverse effects of levamisole in cocaine users: a review and risk assessment. *Arch Toxicol* 2017;91:2303-13.
44. Stepanovic B, Sommerfeld D, Lucas M, von Ungern-Sternberg BS. An update on allergy and anaphylaxis in pediatric anesthesia. *Paediatr Anaesth* 2019;29:892-900.
45. Caron AB. Allergy to multiple local anesthetics. *Allergy Asthma Proc* 2007;28:600-1.
46. Jussi L, Lammintausta K. Sources of sensitization, cross-reactions, and occupational sensitization to topical anaesthetics among general dermatology patients. *Contact Dermatitis* 2009;60:150-4.
47. Swerts S, Van Gasse A, Leysen J, Faber M, Sabato V, Bridts CH, et al. Allergy to illicit drugs and narcotics. *Clin Exp Allergy* 2014;44:307-18.
48. Garvey LH, Ebo DG, Mertes PM, Dewachter P, Garcez T, Kopac P, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. *Allergy* 2019;74:1872-84.
49. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. *Anaesth Intensive Care* 2012;40:216-35.
50. Armentia A, Pineda F, Palacios R, Martin-Gil FJ, Miguel AS, Arenal JJ, et al. Utility of opium seed extract tests in preventing hypersensitivity reactions during surgery. *Allergol Immunopathol (Madr)* 2014;42:56-63.
51. Armentia A, Pineda F, Martin-Armentia B, Palacios R. A useful method to detect opioid allergies. *J Allergy Clin Immunol Pract* 2015;3:829-30.
52. Van Gasse AL, Hagendorens MM, Sabato V, Bridts CH, De Clerck LS, Ebo DG. IgE to poppy seed and morphine are not useful tools to diagnose opiate allergy. *J Allergy Clin Immunol Pract* 2015;3:396-9.
53. Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. *Immunol Allergy Clin North Am* 2014;34:525-46, viii.
54. Lansu K, Karpiak J, Liu J, Huang XP, McCorvy JD, Kroeze WK, et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. *Nat Chem Biol* 2017;13:529-36.
55. Ebo DG, Van der Poorten ML, Elst J, Van Gasse AL, Mertens C, Bridts C, et al. Immunoglobulin E cross-linking or MRGPRX2 activation: clinical insights from rocuronium hypersensitivity. *Br J Anaesth* 2021;126:e27-9.
56. Ebo DG, Bridts CH, Mertens CH, Sabato V. Principles, potential, and limitations of ex vivo basophil activation by flow cytometry in allergology: a narrative review. *J Allergy Clin Immunol* 2021;147:1143-53.
57. Armentia A, Pineda F, Martin-Armentia B, Ramos C, Gil Martin FJ, Palacios R. Endophthalmitis related to lemon allergy in a heroin addict. *Allergol Immunopathol (Madr)* 2016;44:472-4.
58. Chhabra N. Alcohol-induced metabolic alterations—a case-based discussion. Available from: <https://www2.slideshare.net/namarta28/alcohol-induced-metabolic-alterations-a-case-based-discussion/6>. Accessed January 12, 2021.
59. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. *Alcohol Res Health* 2007;30:5-13.
60. Edenberg HJ, McClintick JN. Alcohol dehydrogenases, aldehyde dehydrogenases, and alcohol use disorders: a critical review. *Alcohol Clin Exp Res* 2018;42:2281-97.
61. Cederbaum AI. Alcohol metabolism. *Clin Liver Dis* 2012;16:667-85.
62. Gross ER, Zambelli VO, Small BA, Ferreira JC, Chen CH, Mochly-Rosen D. A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant. *Annu Rev Pharmacol Toxicol* 2015;55:107-27.
63. Matsumura Y, Stiles KM, Reid J, Frenk EZ, Cronin S, Pagovich OE, et al. Gene therapy correction of aldehyde dehydrogenase 2 deficiency. *Mol Ther Methods Clin Dev* 2019;15:72-82.
64. Rajan J, Khan D. Remission of anaphylactic reaction to alcohol. *J Allergy Ther* 2010;1:104.
65. Fernando SL, Clarke LR. Two case reports of life-threatening ethanol-induced anaphylaxis. *Case Rep Dermatol* 2009;1:1-6.
66. Quercia O, Zoccatelli G, Stefanini GF, Mistrello G, Amato S, Bolla M, et al. Allergy to beer in LTP-sensitized patients: beers are not all the same. *Allergy* 2012;67:1186-9.
67. Beezhold DH, Hickey VL, Kostyal DA, Puhl H, Zuidmeer L, van Ree R, et al. Lipid transfer protein from *Hevea brasiliensis* (Hev b 12), a cross-reactive latex protein. *Ann Allergy Asthma Immunol* 2003;90:439-45.

68. Morita E, Yamamura Y, Mihara S, Kameyoshi Y, Yamamoto S. Food-dependent exercise-induced anaphylaxis: a report of two cases and determination of wheat-gamma-gliadin as the presumptive allergen. *Br J Dermatol* 2000;143:1059-63.
69. Picariello G, Mamone G, Cutignano A, Fontana A, Zurlo L, Addeo F, et al. Proteomics, peptidomics, and immunogenic potential of wheat beer (Weissbier). *J Agric Food Chem* 2015;63:3579-86.
70. Bansal RA, Tadros S, Bansal AS. Beer, cider, and wine allergy. *Case Rep Immunol* 2017;2017:7958924.
71. Armentia A, Pineda F, Fernandez S. Wine-induced anaphylaxis and sensitization to hymenoptera venom. *N Engl J Med* 2007;357:719-20.
72. Coons BD, White K. Anaphylaxis to gold tequila. *Ann Allergy Asthma Immunol* 2013;111:70-1.
73. Wuthrich B. Allergic and intolerance reactions to wine. *Allergol Select* 2018;2:80-8.
74. Comas-Baste O, Sanchez-Perez S, Veciana-Nogues MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine intolerance: the current state of the art. *Biomolecules* 2020;10:1181.
75. Maintz L, Novak N. Histamine and histamine intolerance. *Am J Clin Nutr* 2007;85:1185-96.
76. Reese I, Ballmer-Weber B, Beyer K, Fuchs T, Kleine-Tebbe J, Klimek L, et al. German guideline for the management of adverse reactions to ingested histamine: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SGAI). *Allergo J Int* 2017;26:72-9.
77. Siebenhaar F, Melde A, Magerl M, Zuberbier T, Church MK, Maurer M. Histamine intolerance in patients with chronic spontaneous urticaria. *J Eur Acad Dermatol Venereol* 2016;30:1774-7.
78. Cornillier H, Giraudeau B, Samimi M, Munck S, Hacard F, Jonville-Bera AP, et al. Effect of diet in chronic spontaneous urticaria: a systematic review. *Acta Derm Venereol* 2019;99:127-32.
79. Kirschner S, Belloni B, Kugler C, Ring J, Brockow K. Allergenicity of wine containing processing aids: a double-blind, placebo-controlled food challenge. *J Invest Allergol Clin Immunol* 2009;19:210-7.
80. Vassilopoulou E, Karathanos A, Siragakis G, Giavi S, Sinaniotis A, Douladiris N, et al. Risk of allergic reactions to wine, in milk, egg and fish-allergic patients. *Clin Transl Allergy* 2011;1:10.
81. Meyer P, Zanetti S. Detection of traces of ovalbumin and vasein in white and red wines by quantitative Western blotting. *J Food Sci* 2015;80:T2102-9.
82. Rolland JM, Apostolou E, Deckert K, de Leon MP, Douglass JA, Glaspole IN, et al. Potential food allergens in wine: double-blind, placebo-controlled trial and basophil activation analysis. *Nutrition* 2006;22:882-8.
83. Vally H, Thompson PJ, Misso NL. Changes in bronchial hyperresponsiveness following high- and low-sulphite wine challenges in wine-sensitive asthmatic patients. *Clin Exp Allergy* 2007;37:1062-6.
84. Bush RK, Taylor SL, Holden K, Nordlee JA, Busse WW. Prevalence of sensitivity to sulfiting agents in asthmatic patients. *Am J Med* 1986;81:816-20.
85. Bush RK, Taylor SL, Busse W. A critical evaluation of clinical trials in reactions to sulfites. *J Allergy Clin Immunol* 1986;78:191-202.
86. Cardet JC, White AA, Barrett NA, Feldweg AM, Pickner PG, Savage J, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. *J Allergy Clin Immunol Pract* 2014;2:208-13.
87. Wolverson W, Gada S. Systemic contact dermatitis to ethanol. *J Allergy Clin Immunol Pract* 2013;1:195-6.
88. Hon KL, Leung AKC, Ng WGG, Loo SK. Chronic urticaria: an overview of treatment and recent patents. *Recent Pat Inflamm Allergy Drug Discov* 2019;13:27-37.
89. Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. *F1000Res* 2018;7:F1000 Faculty Rev-1885.
90. Bobrove AM. Alcohol-related pain and Hodgkin's disease. *West J Med* 1983;138:874-5.
91. Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. *Clinics (Sao Paulo)* 2018;73:e490s.
92. Valent P, Akin C, Gleixner KV, Sperr WR, Reiter A, Arock M, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. *Int J Mol Sci* 2019;20:2976.
93. Borja-Oliveira C. Alcohol-medication interactions: the acetaldehyde syndrome. *J Pharmacovigilance* 2014;2:5.
94. Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. *Antimicrob Agents Chemother* 2020;64:e02167-19.
95. Weathermon R, Crabb DW. Alcohol and medication interactions. *Alcohol Res Health* 1999;23:40-54.
96. Igelman SJ, Na C, Simpson EL. Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab. *JAAD Case Rep* 2020;6:139-40.
97. Underner M, Peiffer G, Perriot J, Jaafari N. Asthma and cannabis, cocaine or heroin use [in French]. *Rev Mal Respir* 2020;37:572-89.